Oral Minoxidil: The Dermatologist Favorite for Hair Loss

What it is

What Low-Dose Oral Minoxidil Actually Is

Minoxidil was originally approved as an oral antihypertensive at doses of 10–40 mg/day. It was discovered to cause unwanted hair growth as a side effect, which led to the development of topical minoxidil (Rogaine) for hair loss.

Low-dose oral minoxidil (LDOM) is a dermatologist's off-label use of the original oral drug at much lower doses — typically 1.25–5 mg daily for men and 0.625–2.5 mg daily for women — to treat hair loss without the blood-pressure effects seen at antihypertensive doses.

It has become the most-prescribed off-label hair loss treatment among dermatologists in the U.S. and globally over the past 5–7 years.

Evidence

What the Evidence Actually Shows

Multiple peer-reviewed retrospective series of hundreds to thousands of patients (notably Sinclair et al. and the Brazilian and Spanish dermatology groups) have reported significant improvement in androgenetic alopecia, female pattern hair loss, telogen effluvium, traction alopecia, and several scarring alopecias. A 2024 meta-analysis confirmed efficacy comparable to or exceeding topical minoxidil.

Onset is typically visible by 3–6 months; full effect by 9–12 months. As with topical minoxidil, an initial shedding phase in the first 4–8 weeks is common and not a sign of failure.

It does not regrow hair on bald (long-standing scarring) scalp. The active drug requires functional follicles to work on.

Dosing

Typical Dosing in 2026 Dermatology Practice

• ·Men: 2.5–5 mg daily (some start at 1.25 mg and titrate).
• ·Women: 0.625–2.5 mg daily (often starting at 0.625 or 1.25).
• ·Dose adjustments based on response, side effects, and lower-extremity edema monitoring.

Many dermatologists check baseline blood pressure and may order a basic metabolic panel before starting, with periodic check-ins.

Side effects

Side Effects and What to Watch For

• ·Hypertrichosis (unwanted hair growth on face, arms, body): the most common side effect. Dose-dependent; reversible with discontinuation.
• ·Lower-extremity edema: occurs in a meaningful minority of patients. Often manageable with dose reduction or diuretic adjustment in patients with concurrent indication.
• ·Palpitations or tachycardia: less common at low doses; warrants dose review or discontinuation.
• ·Postural hypotension: rare at LDOM doses but possible — particularly in patients on other antihypertensives.
• ·Rare: pericardial effusion at higher doses (a class warning from antihypertensive-dose minoxidil); generally not seen at LDOM doses but reason for dermatologist supervision rather than self-prescription.

Who shouldn't take it

Who Shouldn't Use Low-Dose Oral Minoxidil

• ·Patients with significant cardiovascular disease, heart failure, or pericardial disease.
• ·Patients with pheochromocytoma (contraindicated).
• ·Pregnancy and breastfeeding (not recommended).
• ·Patients on multiple antihypertensives or with significant orthostatic intolerance.
• ·Patients unable to commit to dermatologist follow-up for monitoring.

In context

Where Oral Minoxidil Fits Alongside Other Treatments

• ·Often combined with finasteride or dutasteride in men for androgenetic alopecia — additive effect.
• ·Often combined with spironolactone in women for female pattern hair loss.
• ·Reasonable add-on to PRP, microneedling, and exosome therapy for incremental effect.
• ·For GLP-1 associated hair shedding (telogen effluvium from rapid weight loss), LDOM can shorten and lessen the shedding while the underlying trigger resolves — see our GLP-1 hair loss guide.